PHASE 1B STUDY OF VENETOCLAX COMBINED WITH BORTEZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Moreau, P. [1 ]
Chanan-Khan, A. [2 ]
Roberts, A. W. [3 ]
Agarwal, A. [4 ]
Facon, T. [5 ]
Kumar, S. [2 ]
Touzeau, C. [1 ]
Diehl, S. [6 ]
Cordero, J. [6 ]
Ross, J. [6 ]
Munasinghe, W. [6 ]
Zhu, M. [6 ]
Salem, A. H. [6 ]
Leverson, J. [6 ]
Maciag, P. [6 ]
Verdugo, M. [6 ]
Harrison, S. J. [7 ]
机构：
[1] CHU Nantes, Hotel Dieu HME, Nantes, France
[2] Mayo Clin, Rochester, MN USA
[3] Royal Melbourne Hosp, Melbourne, Vic, Australia
[4] Univ Arizona, Ctr Canc, Tucson, AZ USA
[5] Hop Huriez, CHRU Lille, Lille, France
[6] AbbVie Inc, N Chicago, IL USA
[7] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P272
引用
收藏
页码：81 / 82
页数：2
相关论文
共 50 条
  • [1] A PHASE 1B STUDY OF VENETOCLAX COMBINED WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Moreau, P.
    Chanan-Khan, A.
    Roberts, A. W.
    Agarwal, A. B.
    Facon, T.
    Kumar, S.
    Touzeau, C.
    Cordero, J.
    Ross, J.
    Munasinghe, W.
    Jia, J.
    Salem, A. H.
    Leverson, J.
    Maciag, P.
    Verdugo, M.
    Harrison, S. J.
    HAEMATOLOGICA, 2017, 102 : 169 - 169
  • [2] A Phase 1b Study of Venetoclax Combined with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Moreau, Philippe
    Chanan-Khan, Asher
    Roberts, Andrew W.
    Agarwal, Amit B.
    Facon, Thierry
    Kumar, Shaji
    Touzeau, Cyrille
    Cordero, Jaclyn
    Ross, Jeremy
    Munasinghe, Wijith
    Jia, Jia
    Salem, Ahmed H.
    Leverson, Joel
    Maciag, Paulo
    Verdugo, Maria
    Harrison, Simon J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E16 - E16
  • [3] Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
    Moreau, Philippe
    Chanan-Khan, Asher Alban Akmal
    Roberts, Andrew Warwick
    Agarwal, Amit
    Facon, Thierry
    Kumar, Shaji
    Touzeau, Cyrille
    Diehl, Susan
    Cordero, Jaclyn
    Ross, Jeremy A.
    Munasinghe, Wijith
    Zhu, Ming
    Salem, Ahmed H.
    Leverson, Joel
    Maciag, Paulo Cesar
    Verdugo, Maria E.
    Harrison, Simon J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma
    Moreau, Philippe
    Chanan-Khan, Asher A.
    Roberts, Andrew W.
    Agarwal, Amit B.
    Facon, Thierry
    Kumar, Shaji
    Touzeau, Cyrille
    Cordero, Jaclyn
    Ross, Jeremy
    Munasinghe, Wijith
    Jia, Jia
    Salem, Ahmed H.
    Leverson, Joel
    Maciag, Paulo
    Verdugo, Maria
    Harrison, Simon J.
    BLOOD, 2016, 128 (22)
  • [5] A phase 1b study of oral panobinostat and IV bortezomib in relapsed or relapsed and refractory multiple myeloma
    San-Miguel, J. F.
    Richardson, P. G. G.
    Sezer, O.
    Guenther, A.
    Siegel, D. S. D.
    Blade, J.
    LeBlanc, R.
    Sutherland, H. J.
    Mateos, M.
    Gramatzki, M.
    Hazell, K. M.
    Bengoudifa, B.
    Bourquelot, P. M.
    Anderson, K. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] VENETOCLAX (ABT-199/GDC-0199) IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 1B RESULTS
    Moreau, P.
    Chanan-Khan, A. A.
    Roberts, A.
    Agarwal, A.
    Facon, T.
    Lebovic, D.
    Touzeau, C.
    Darden, D.
    Morris, L.
    Ross, J.
    Salem, A.
    Munasinghe, W.
    Zhu, M.
    Leverson, J.
    Enschede, S.
    Humerickhouse, R.
    Harrison, S.
    HAEMATOLOGICA, 2015, 100 : 91 - 92
  • [7] A Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Kumar, Shaji
    Harrison, Simon J.
    Cavo, Michele
    De La Rubia, Javier
    Popat, Rakesh
    Gasparetto, Cristina J.
    Hungria, Vania
    Salwender, Hans J.
    Suzuki, Kenshi
    Kim, Inho
    Punnoose, Elizabeth
    Hong, Wan-Jen
    Freise, Kevin J.
    Sood, Anjla
    Jalaluddin, Muhammad
    Ross, Jeremy
    Ward, James E.
    Maciag, Paulo
    Moreau, Philippe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E31 - E31
  • [8] A Phase 1b Study of Oprozomib with Dexamethasone or Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
    Hari, Parameswaran
    Schroeder, Mark A.
    Berenson, James R.
    Jakubowiak, Andrzej
    Kaufman, Jonathan L.
    Voorhees, Peter M.
    Fujii, Hisaki
    Yang, Zhao
    Galimi, Francesco
    Shain, Kenneth H.
    BLOOD, 2018, 132
  • [9] Oncolytic Reovirus Immune Priming: A Phase 1b Study of Reolysin with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Kelly, Kevin R.
    Wu, Kaijin
    Tsao-Wei, Denice
    Groshen, Susan
    Triche, Timothy Junius, Jr.
    Mohrbacher, Ann
    Chang, Grace
    Fernando, Donna
    Siddiqi, Imran N.
    Coffey, Matt
    Gill, George
    Lee, Amy
    Carew, Jennifer S.
    Nawrocki, Steffan T.
    BLOOD, 2016, 128 (22)
  • [10] Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study
    Biran, Noa
    Siegel, David
    Berdeja, Jesus G.
    Raje, Noopur
    Cornell, Robert Frank
    Alsina, Melissa
    Kovacsovics, Tibor
    Fang, Belle
    Kimball, Amy S.
    Landgren, Ola
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (07) : 794 - 802
12345